TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10077720
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy (control group)
Study: 11345031
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Ukrain (5 mg every second day, 10 injections altogether)
Study: 11345031
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Ukrain (10 mg every second day, 10 injections altogether)
Study: 3911832
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (350,000 to 500,000 IU daily)
Study: 3911832
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (high dose)
Study: 30696254
Drug: Let's Talk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Let's Talk About Children plus treatment as usual (n=20)
Study: 30696254
Drug: Wait list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait list control (treatment as usual) (n=19)
Study: 24973002
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin (bLf) oral spray and oral piroxicam
Study: 24973002
Drug: Oral piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral piroxicam
Study: 24973002
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin (bLf) oral spray and piroxicam
Study: 16321598
Drug: Foods enriched
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foods enriched in long-chain n-3 fatty acids (1 g/day)
Study: 11923244
Drug: Low-viscosity solutions
Normalized name: polyethylene terephthalate (intrinsic viscosity 0.40-0.70)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-viscosity solutions (eta = 2.7‐7.7 mPa/sec)
Study: 11923244
Drug: High-viscosity gel
Normalized name: Mineral Oil (high Viscosity)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-viscosity gel (eta approximately equal 30,000 mPa/sec)
Study: 8553083
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and weekly high-dose 5-FU/FA regimen
Study: 8553083
Drug: Dose level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 4 (500 mg/m2 FA, 2.0 g/m2 5-FU, and 175 mg/m2 paclitaxel)
Study: 30621712
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy
Study: 31296602
Drug: Lightning Process,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lightning Process, a neurolinguistic programming intervention, details on dosage and duration not available.
Study: 23127204
Drug: Aqueous progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aqueous progesterone formulation (100 mg) administered by subcutaneous injection
Study: 23127204
Drug: Aqueous progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aqueous progesterone formulation (25 mg and 50 mg) administered by subcutaneous injection once daily for 11 days
Study: 23127204
Drug: Intramuscular reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular reference oily product
Study: 12495804
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg buprenorphine
Study: 11292003
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg buprenorphine
Study: 21854290
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg buprenorphine
Study: 14665554
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (HES) solution
Study: 11687764
Drug: Acute sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute sodium bicarbonate ingestion (0.5 g x kg(‐1) body mass)
Study: 11687764
Drug: Chronic sodium
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic sodium bicarbonate ingestion (0.5 g x kg(‐1) body mass daily for six days)
Study: 9140693
Drug: Procainamide (bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (bid formulation) 1000, 2000, or 4000 mg/d
Study: 9140693
Drug: Procainamide (qid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (qid formulation)
Study: 9140693
Drug: Procainamide (bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (bid formulation)
Study: 27849419
Drug: Combination (pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (pulse group DCP)
Study: 11196420
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg/d)
Study: 18038223
Drug: Cognitive measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive measures (e.g., rapid visual information processing task, cued Go/No-Go task)
Study: 11951074
Drug: Doxofylline 400
Normalized name: Doxofylline 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxofylline 400 mg t.i.d.
Study: 11951074
Drug: Theophylline 250
Normalized name: theophylline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 250 mg t.i.d. (active control)
Study: 11951074
Drug: Doxofylline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxofylline 200 mg t.i.d.
Study: 11951074
Drug: Theophylline 250
Normalized name: theophylline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 250 mg t.i.d.
Study: 30878017
Drug: Patisiran, 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran, 0.3 mg/kg, via intravenous infusion once every 3 weeks for 18 months
Study: 27876004
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg from recruitment until 36+0 weeks or delivery, whichever occurs sooner, in addition to standard high risk care (which includes aspirin 100 mg daily and calcium 1000-1500 mg daily)
Study: 27876004
Drug: Standard high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard high risk care (which includes aspirin 100 mg daily and calcium 1000-1500 mg daily)
Study: 23795582
Drug: Early surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surfactant (ES) treatment (200 mg/kg Curosurf® within 1 hour after birth)
Study: 23795582
Drug: Early surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surfactant (ES) treatment
Study: 23795582
Drug: Late selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late selective (LS) treatment
Study: 23795582
Drug: Both ES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ES and LS treatments
Study: 6340424
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml cod liver oil (CLO) daily for 6 weeks
Study: 16983507
Drug: Carbamazepine (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (Treatment A)
Study: 16983507
Drug: Control (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Treatment B)
Study: 11925375
Drug: Biphasic oral
Normalized name: Kariva, biphasic oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic oral contraceptive (norethindrone 500 microg/ethinyl estradiol 35 microg for 10 days, followed by norethindrone 1000 microg/ethinyl estradiol 35 microg for 11 days)
Study: 11925375
Drug: Monophasic oral
Normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic oral contraceptive (norethindrone acetate 1500 microg/ethinyl estradiol 30 microg daily)
Study: 24092872
Drug: Prednisolone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (2 mg/kg/d for 3 days)
Study: 30068285
Drug: Thyroid peroxidase
Normalized name: Thyroid peroxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid peroxidase antibodies
Study: 26016820
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) capsule containing 28 mg memantine extended release (ER) and 10 mg donepezil
Study: 26016820
Drug: FDC capsule
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC capsule taken while fasting
Study: 26016820
Drug: Co-administered memantine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administered memantine ER and donepezil
Study: 21996634
Drug: Comprehensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive intervention program (SPRING) including exercise classes, nutrition classes, and bathing, twice a week for 3 months
Study: 11592358
Drug: Leflunomide (LEF)
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide (LEF) 20 mg/day, loading dose 100 mg x 3 days
Study: 9555919
Drug: Baseline measurements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline measurements taken for 6 weeks (phase AI) and a 3-week period without treatment (phase AII).
Study: 3138445
Drug: Cyclic total
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic total parenteral nutrition (infusion between 5 pm and 9 am)
Study: 3138445
Drug: Standard continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard continuous total parenteral nutrition (infusion 24 hr/day)
Study: 8078438
Drug: Cyclic total
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic total parenteral nutrition
Study: 3138445
Drug: Standard continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard continuous total parenteral nutrition
Study: 25927522
Drug: Aseptic, purified,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aseptic, purified, cryopreserved, infectious P. falciparum sporozoites (Sanaria® PfSPZ Challenge) administered intramuscularly (IM)
Study: 20021294
Drug: Transdermal rivastigmine
Normalized name: rivastigmine Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rivastigmine
Study: 20021294
Drug: Oral rivastigmine
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral rivastigmine
Study: 22129897
Drug: Oral lipoceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lipoceutical glutathione
Study: 22129897
Drug: Transdermal glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glutathione
Study: 18023600
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 40 mcg inhaled via MDI
Study: 18023600
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 40 mcg inhaled via MDI plus ondansetron 8 mg oral, qid, for 2 days
Study: 18023600
Drug: Ondansetron (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (single or repeated doses)
Study: 16448522
Drug: Gliclazide MR
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide MR (once-daily administration)
Study: 16448522
Drug: Gliclazide (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (twice-daily administration)
Study: 14671407
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg GH/m(2) per day (group B, n = 38)
Study: 14671407
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg GH/m(2) per day (n = 60)
Study: 14671407
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (1 mg or 2 mg GH/m(2) per day)
Study: 14671407
Drug: After discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: After discontinuation of GH therapy
Study: 10193729
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg daily for two weeks (phase I)
Study: 10193729
Drug: Simvastatin average
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin average dose of 24 mg/d for three months (phase II)
Study: 10193729
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg/day added to simvastatin for two weeks (phase III)
Study: 10937931
Drug: Metoprolol (beta-blocker)
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol (beta-blocker)
Study: 1975526
Drug: Nifedipine (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (calcium antagonist)
Study: 342313
Drug: Inactivated whole‐virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated whole‐virus vaccine (H0N2)
Study: 31495497
Drug: Inebilizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inebilizumab (300 mg intravenous on days 1 and 15)
Study: 23627791
Drug: Wound-specific oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound-specific oral nutrition supplement (enriched with arginine, vitamin C, and zinc)
Study: 23627791
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral nutrition supplement
Study: 23627791
Drug: Wound-specific oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound-specific oral nutrition supplement
Study: 20887370
Drug: Brivaracetam (BRV)
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Brivaracetam (BRV) 10 mg
Study: 20887370
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 500 mg
Study: 22711428
Drug: Lorazepam (LZP)
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam (LZP) 2 mg
Study: 19371826
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control (IGC) (n = 25; glucose 80 to 140 mg/dl)
Study: 19371826
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic control (CGC) (n = 25; glucose 180 to 200 mg/dl)
Study: 15155310
Drug: Heparin-coated circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuit (Group 1)
Study: 10410575
Drug: Insulin levels
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin levels in patients with hyperinsulinemia
Study: 2845769
Drug: CAMP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMP (cyclophosphamide 300 mg/m2 i.v., adriamycin 20 mg/m2 i.v., methotrexate 15 mg/m2 i.v. days 1 and 8, procarbazine 100 mg/m2 orally from day 1 to day 10, every 4 weeks)
Study: 2845769
Drug: DE (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DE (cisplatin 20 mg/m2 i.v. for five consecutive days and etoposide 75 mg/m2 i.v. on the same days, every 3 weeks)
Study: 31896735
Drug: Vibratory positional
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibratory positional therapy (PT)
Study: 31896735
Drug: Patient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient treatment preference
Study: 31320726
Drug: CAVA device
Normalized name: Ecklonia cava
DrugBank: Ecklonia cava (DB19252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAVA device (Continuous Ambulatory Vestibular Assessment), worn near continuously for up to thirty days, with daily replacement of electrodes.
Study: 28059849
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (atorvastatin 60 mg/day)
Study: 28059849
Drug: Moderate statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate statin therapy (atorvastatin 20 mg/day or rosuvastatin 10 mg/day)
Study: 28059849
Drug: Both intensive
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intensive and moderate statin therapy
Study: 17974278
Drug: Nadaplatin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadaplatin 30 mg/m2 dl‐3, paclitaxol 175 mg/m2 dl, repeated every 4 weeks
Study: 17974278
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m2 dl‐3, paclitaxol 175 mg/m2 dl, repeated every 4 weeks
Study: 15590950
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ICD therapy)
Study: 11561110
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection of triamcinolone hexacetonide and xylocaine
Study: 11561110
Drug: Palpation-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation-guided injection of triamcinolone hexacetonide and xylocaine
Study: 21458143
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection
Study: 11561110
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection and palpation-guided injection
Study: 30973454
Drug: Continuation ECT
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation ECT (4 weekly sessions, followed by 4 sessions every 2 weeks, and 2 monthly sessions for a total of 10 sessions)
Study: 25251838
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment group (MSoBT program)
Study: 17373978
Drug: 308-nm xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm xenon chloride excimer laser therapy + topical calcipotriol (Daivonex) applied twice daily to one side of the body
Study: 17373978
Drug: 308-nm xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm xenon chloride excimer laser therapy alone
Study: 12190715
Drug: Immediate multi-family
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate multi-family psychoeducation groups (MFPG) plus treatment as usual (TAU)
Study: 12190715
Drug: Wait-list +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list + treatment as usual (TAU)
Study: 9523850
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg i.v. methylprednisolone before and saline after TDI (group 2)
Study: 9523850
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg i.v. methylprednisolone before and after TDI (group 3)
Study: 15362028
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg/kg/day)
Study: 29221483
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy
Study: 24526136
Drug: 33 μg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33 μg/kg/day growth hormone (GH) for 260 weeks
Study: 24526136
Drug: 67 μg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 67 μg/kg/day growth hormone (GH) for 260 weeks
Study: 9512836
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg daily)
Study: 8791975
Drug: Sucralfate gel
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate gel (1 g b.d.)
Study: 1292969
Drug: Erdosteine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine (900 mg/day for two weeks)
Study: 3630598
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both techniques
Study: 26514967
Drug: OXC +
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OXC + verapamil (300 mg OXC/12 h and 80 mg verapamil/8 h for 5 days)
Study: 26514967
Drug: OXC monotherapy
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OXC monotherapy (300 mg OXC/12 h for 5 days)
Study: 24481580
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dexketoprofen (GD)
Study: 11898004
Drug: 0.1% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tacrolimus ointment
Study: 20169301
Drug: Corticosteroid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid regimen (hydrocortisone acetate 1% ointment for head and neck, hydrocortisone butyrate 0.1% ointment for trunk and limbs)
Study: 17570057
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of Divalproex sodium (DVP)
Study: 17570057
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of Divalproex sodium (DVP)
Study: 16251796
Drug: Prenatal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal and postnatal fluoride supplements
Study: 16983056
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg
Study: 11045181
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluvastatin (20 mg daily) and fenofibrate (200 mg daily)
Study: 8736279
Drug: Full replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full replacement therapy (thyroxine)